HER2+ (HER2-positive) breast cancer is a type of breast cancer subtype with strong aggressiveness and poor prognosis. With the approval of more new targeted drugs for clinical application, the prognosis of HER2+ breast cancer patients continues to improve. In the absence of previous anti-HER2 targeted therapy, patients with HER2+ have a higher risk of recurrence. After anti-HER2 therapy, the risk of recurrence is significantly reduced. In recent years, the emergence of antibody-coupled (ADC) drugs has brought the treatment of HER2+ breast cancer patients into a new era, but there are still some unsolved problems. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dr.Javier Cortes of the Vall d'Hebron Institute of Cancer in Barcelona, Spain, to summarize and look forward to the changes in the field of HER2+ advanced breast cancer.

The decisions faced by cancer patients are often many and complex. At present, the doctor-patient co-decision model is widely used in cancer patients. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) "Patient advocacy session: Complexities of shared decision making "featured experts discussing complexities of shared decision making among patients.Oncology Frontier invited Dr.Ginny Mason, the host of the show, to introduce the common psychological problems of breast cancer patients and how to deal with them.